Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bronson Crouch
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Beta
- 1.94
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -5.03
Financials
Revenue
$0.00-100.0%Net Income
$-4.30MEBITDA
$-7.57MFree Cash Flow
$-4.64MEPS (diluted)
$-0.63Shares Outstanding (diluted)
6.78M+5.8%Operating Expenses
$5.40MCash & Debt
$69.68MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-71.37M | $-10.70 |
| 2024 | $0.00 | $-74.14M | $-11.39 |
| 2023 | $0.00 | $-156.09M | $-24.00 |
| 2022 | $0.00 | $-223.18M | $-34.46 |
| 2021 | $0.00 | $-156.79M | $-29.60 |
| 2020 | $138.0K | $-37.74M | $-5.89 |
| 2019 | $0.00 | $-6.45M | $-1.01 |
Valuation
TILhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·5h ago·Negative
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma 62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Reinforces Ongoing TILVANCE-301 Phase 3 Trial PHILADELPHIA and M…
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026 Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Treated Soft Tissue Sarcomas PHILADELPHIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on inno…
View source ↗ - Newsmarketbeat.com·34d ago·Positive
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains Iovance Biotherapeutics NASDAQ: IOVA said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin.
View source ↗ - Newsglobenewswire.com·70d ago·Neutral
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update. Recent Highlights: Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therap…
View source ↗
Earnings
Mon, Nov 16(in 3 weeks)
Consensus estimate $-0.17 per share
Typical surprise -0.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.63 vs $-0.35miss
- Fri, May 15$-0.62 vs $-0.62beat
- Fri, Mar 27$-1.21 vs $-2.31beat
- Thu, Nov 13$-2.01 vs $-2.00miss
- Wed, Aug 13$-3.24 vs $-1.72miss
- Tue, May 13$-4.32 vs $-2.02miss
Estimates and results for TIL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TIL officers and directors.
- Bought
- $45.0m
- Sold
- $702k
10 trades
2 trades
- Laumas Sandeepsold
- Laumas Sandeepsold
- Vivo Capital Ix, Llcbought
- Shah Nimish Pbought
- Shah Nimish Pbought
- Shah Nimish Pbought
- Shah Nimish Pbought
- Shah Nimish Pbought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TIL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.